PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Launchphenylephrine hydrochloride injection, solution
NDAINTRAVENOUSSOLUTION
Approved
May 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
3/8 — Basic
PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE (phenylephrine hydrochloride injection, solution) by Dr. Reddy's Laboratories is adrenergic alpha1-agonists [moa]. First approved in 2025.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Phenylephrine HCl injection is an alpha-1 adrenergic agonist administered intravenously to treat hypotension in acute clinical settings. It works by stimulating alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. This IV solution combines the active ingredient with 0.9% sodium chloride for compatibility and stability.
Growth18.3 years to LOE
Recent NDA approval (May 2025) indicates an early-stage launch phase with growing commercial infrastructure and team-building opportunities ahead.
Mechanism of Action
Adrenergic alpha1-Agonists
Pharmacologic Class:
alpha-1 Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this freshly approved IV vasopressor positions you in critical care commercialization during a launch phase with opportunities to build market presence in hospitals and ICUs. Roles span commercial teams, medical affairs, and operations, with career value in acute-care market access expertise and manufacturing scale-up execution.
Brand Manager
Worked on PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.